The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Pronin I.N.

Burdenko Neurosurgical Center

Khokhlova E.V.

Burdenko National Medical Scientific Center for Neurosurgery

Konakova T.A.

Burdenko National Medical Scientific Center for Neurosurgery

Maryashev S.A.

Burdenko National Medical Scientific Center for Neurosurgery

Pitskhelauri D.I.

Skolkovo Institute of Science and Technology

Batalov A.I.

Burdenko Neurosurgical Center

Postnov A.A.

Burdenko National Medical Scientific Center for Neurosurgery;
National Research Nuclear University MEPhI (Moscow Engineering Physics Institute);
Lebedev Physical Institute of the Russian Academy of Sciences

Positron emission tomography with 11C-methionine in primary brain tumor diagnosis

Authors:

Pronin I.N., Khokhlova E.V., Konakova T.A., Maryashev S.A., Pitskhelauri D.I., Batalov A.I., Postnov A.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(8): 51‑56

DOI: 10.17116/jnevro202012008151

Views: 10033

Downloaded: 225

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Pronin IN, Khokhlova EV, Konakova TA, Maryashev SA, Pitskhelauri DI, Batalov AI, Postnov AA. Positron emission tomography with 11C-methionine in primary brain tumor diagnosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(8):51‑56. (In Russ.)
https://doi.org/10.17116/jnevro202012008151

 
МСФ на ЯМ
Close metadata

OBJECTIVE

To investigate the variations in 11C-methionine uptake in the intact brain tissue and in glial brain tumors of different types.

MATERIAL AND METHODS

Forty patients (21 men, 19 women) with gliomas, Grade I-IV, underwent 11C-methionine PET-CT and contrast-enhanced MRI. Standardized uptake value (SUV), tumor-to-normal (T/N) ratios and tumor volume were analyzed.

RESULTS

The high inter-subject variability was detected in the intact brain tissue (SUV in the frontal lobe (FL) varies from 0.47 to 1.73). Amino acid metabolism was more active in women than in men (FL SUV 1.32±0.22 and 1.05±0.24, respectively). T/N ratio better differentiates gliomas by the degree of anaplasia compared to SUV. Gliomas of Grade III (T/N=2.64±0.98) were significantly different (p<0.05) from those of Grade IV (T/N=3.83±0.75). The lowest level of methionine uptake was detected in diffuse astrocytomas (T/N=1.52±0.57), which was lower than with anaplastic astrocytomas (T/N=2.34±0.77, p<0.05).

CONCLUSIONS

11C-methionine PET-CT was informative in the high/low degree of malignancy differentiation (T/N 1.66±0.71 for Grade I-II and 3.18±1.06 for Grade III-IV, p<0.05). The method was also useful in separating astrocytomas of Grade II and III. The considerable variation of SUV in the intact brain tissue as well as the difference in uptake between selected areas of the brain were revealed.

Keywords:

11C-methionine PET-CT
brain tumors
differential diagnosis of gliomas

Authors:

Pronin I.N.

Burdenko Neurosurgical Center

Khokhlova E.V.

Burdenko National Medical Scientific Center for Neurosurgery

Konakova T.A.

Burdenko National Medical Scientific Center for Neurosurgery

Maryashev S.A.

Burdenko National Medical Scientific Center for Neurosurgery

Pitskhelauri D.I.

Skolkovo Institute of Science and Technology

Batalov A.I.

Burdenko Neurosurgical Center

Postnov A.A.

Burdenko National Medical Scientific Center for Neurosurgery;
National Research Nuclear University MEPhI (Moscow Engineering Physics Institute);
Lebedev Physical Institute of the Russian Academy of Sciences

Received:

13.07.2019

Accepted:

08.08.2019

List of references:

  1. Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Del Fiore G, Luxen A, Reznik M. Preoperative Evaluation of 54 Gliomas by PET with Fluorine-18-Fluorodeoxyglucose and/or Carbon-11. Methionine Journal of Nuclear Medicine. 1998;39:778-785. 
  2. Kim S, Chung J, Im S, Jeong J, Lee D, Kim D, Jung H, Lee M. 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET. European Journal of Nuclear Medicine and Molecular Imaging. 2004;32(1):52-59.  https://doi.org/10.1007/s00259-004-1598-6
  3. Singhal T, Narayanan T, Jacobs M, Bal C, Mantil J. 11C-Methionine PET for Grading and Prognostication in Gliomas: A Comparison Study with 18F-FDG PET and Contrast Enhancement on MRI. Journal of Nuclear Medicine. 2012;53(11):1709-1715. https://doi.org/10.2967/jnumed.111.102533
  4. Zhao C, Zhang Y, Wang J. A Meta-Analysis on the Diagnostic Performance of 18F-FDG and 11C-Methionine PET for Differentiating Brain Tumors. American Journal of Neuroradiology. 2013;35(6):1058-1065. https://doi.org/10.3174/ajnr.a3718
  5. Mineura K, Sasajima T, Suda Y, Kowada M, Shishido F, Uemura K. Amino Acid Study of Cerebral Gliomas Using Positron Emission Tomography. Neurol Med Chir (Tokyo). 1990;30(13):997-1002. https://doi.org/10.2176/nmc.30.997
  6. Hatazawa J, Ishiwata K, Itoh M, Kameyama M, Kubota K, Ido T, Matsuzawa T, Yoshimoto T, Watanuki S, Seo S. Quantitative evaluation of L-[methyl-C-11] methionine uptake in tumor using positron emission tomography. Journal of Nuclear Medicine: Official Publication. Society of Nuclear Medicine. 1989;30(11):1809-1813.
  7. Takano K, Kinoshita M, Arita H, Okita Y, Chiba Y, Kagawa N, Fujimoto Y, Kishima H, Kanemura Y, Nonaka M, Nakajima S, Shimosegawa E, Hatazawa J, Hashimoto N, Yoshimine T. Diagnostic and Prognostic Value of 11C-Methionine PET for Nonenhancing Gliomas. American Journal of Neuroradiology. 2015;37(1):44-50.  https://doi.org/10.3174/ajnr.a4460
  8. Lee IH, Piert M, Gomez-Hassan D, Junck L, Rogers L, Hayman J, Ten Haken RK, Lawrence TS, Cao Y, Tsien C. Association of 11C-Methionine PET Uptake With Site of Failure After Concurrent Temozolomide and Radiation for Primary Glioblastoma Multiforme. International Journal of Radiation Oncology•Biology•Physics. 2009;73(2):479-485.  https://doi.org/10.1016/j.ijrobp.2008.04.050
  9. Tsien CI, Brown D, Normolle D, Schipper M, Piert M, Junck L, Heth J, Gomez-Hassan D, Ten Haken RK, Chenevert T, Cao Y, Lawrence T. Concurrent Temozolomide and Dose-Escalated Intensity-Modulated Radiation Therapy in Newly Diagnosed Glioblastoma. Clinical Cancer Research. 2011;18(1):273-279.  https://doi.org/10.1158/1078-0432.ccr-11-2073
  10. Yoo M, Paeng J, Cheon G, Lee D, Chung J, Kim E, Kang K. Prognostic Value of Metabolic Tumor Volume on 11C-Methionine PET in Predicting Progression-Free Survival in High-Grade Glioma. Nuclear Medicine and Molecular Imaging. 2015;49(4):291-297.  https://doi.org/10.1007/s13139-015-0362-0
  11. Iacovelli R, Alesini D, Palazzo A, Trenta P, Santoni M, De Marchis L, Cascinu S, Naso G, Cortesi E. [11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas. ISRN Oncology. 2014;1-6.  https://doi.org/10.1155/2014/463152
  12. Ullrich R, Kracht L, Brunn A, Herholz K, Frommolt P, Miletic H, Deckert M, Heiss W, Jacobs A. Methyl-L-11C-Methionine PET as a Diagnostic Marker for Malignant Progression in Patients with Glioma. Journal of Nuclear Medicine. 2009;50(12):1962-1968. https://doi.org/10.2967/jnumed.109.065904
  13. Skvortsova TYu, Brodskaya ZL, Gurchin AF. Vozmozhnosti pozitronno-emissionnoj tomografii s 11C-metioninom v raspoznavanii psevdoprogressii tserebral’nykh gliom posle kombinirovannogo lecheniya. Problems of Neurosurgery named after N.N. Burdenko. 2014;78(4):45-52. (In Russ.)
  14. Sadeghi N, Salmon I, Decaestecker C, Levivier M, Metens T, Wikler D, Denolin V, Rorive S, Massager N, Baleriaux D, Goldman S. Stereotactic Comparison among Cerebral Blood Volume, Methionine Uptake, and Histopathology in Brain Glioma. American Journal of Neuroradiology. 2007;28(3):455-461. 
  15. Galldiks N, Ullrich R, Schroeter M, Fink G, Kracht L. Volumetry of [11C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme. Eur J Nucl Med Mol Imaging. 2009; 37(1):84-92.  https://doi.org/10.1007/s00259-009-1219-5
  16. Berntsson SG, Falk A, Savitcheva I, Godau A, Zetterling M, Hesselager G, Alafuzoff I, Larsson EM, Smits A. Perfusion and diffusion MRI combined with 11C-methionine PET in the preoperative evaluation of suspected adult low-grade gliomas. J Neurooncol. 2013;114(2):241-249.  https://doi.org/10.1007/s11060-013-1178-3
  17. De Witte O, Goldberg I, Wikler D, Rorive S, Damhaut P, Monclus M, Salmon I, Brotchi J, Goldman S. Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg. 2001; 95(5):746-750.  https://doi.org/10.3171/jns.2001.95.5.0746
  18. Tsuyuguchi N, Takami T, Sunada I, Iwai Y, Yamanaka K, Tanaka K, Nishikawa M, Ohata K, Torii K, Morino M, Nishio A, Hara M. Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery — In malignant glioma. Ann Nucl Med. 2004;18(4):291-296.  https://doi.org/10.1007/bf02984466
  19. Pronin AI, Dolgushin MB, Lyuosev AS, Odzharova AA, Nevzorov DI, Nechipay EA, Gaspayan TG. Capabilities of 18F-FET PET/CT in a patient with brain glioma (a case report and literature review). Problems of Neurosurgery named after N.N. Burdenko. 2018;82(2):95. (In Russ.) https://doi.org/10.17116/oftalma201882295-99
  20. Galldiks N, Langen K, Pope W. From the clinician’s point of view — What is the status quo of positron emission tomography in patients with brain tumors? Neuro-oncology. 2015;17(11):1434-1444. https://doi.org/10.1093/neuonc/nov118
  21. Cicone F, Minniti G, Oliva MA, Carideo L, Prior JO, Scopinaro F, Giangaspero F, Arcella A. Expression of large neutral amino acid transporters LAT1 and LAT2 in medulloblastoma. Brain Tumor Pathol. 2017;34(4):179-181.  https://doi.org/10.1007/s10014-017-0296-6
  22. Derlon JM, Bourdet C, Bustany P, Chatel M, Theron J, Darcel F, Syrota A. [11C]L-methionine uptake in gliomas. Neurosurgery. 1989;25(5):720-728.  https://doi.org/10.1097/00006123-198911000-00006
  23. Kato T, Shinoda J, Oka N, Miwa K, Nakayama N, Yano H, Maruyama T, Muragaki Y, Iwama T. Analysis of 11C-methionine Uptake in Low-Grade Gliomas and Correlation with Proliferative Activity. American Journal of Neuroradiology. 2008;29(10):1867-1871. https://doi.org/10.3174/ajnr.a1242
  24. Saito T, Maruyama T, Muragaki Y, Tanaka M, Nitta M, Shinoda J, Aki T, Iseki H, Kurisu K, Okada Y. 11C-Methionine Uptake Correlates with Combined 1p and 19q Loss of Heterozygosity in Oligodendroglial Tumors. American Journal of Neuroradiology. 2012;34(1):85-91.  https://doi.org/10.3174/ajnr.a3173
  25. Giammarile F, Cinotti LE, Jouvet A, Ramackers JM, Saint Pierre G, Thiesse P, Jouanneau E, Guyotat J, Pelissou-Guyotat I, Setiey A, Honnorat J, Le Bars D, Frappaz D. High and Low Grade Oligodendrogliomas (ODG): Correlation of Amino-Acid and Glucose Uptakes Using PET and Histological Classifications. J Neurooncol. 2004;68(3):263-274.  https://doi.org/10.1023/b:neon.0000033384.43417.82
  26. Qiao Z, Zhao X, Wang K, Zhang Y, Fan D, Yu T, Shen H, Chen Q, Ai L. Utility of Dynamic Susceptibility Contrast Perfusion-Weighted MR Imaging and 11C-Methionine PET/CT for Differentiation of Tumor Recurrence from Radiation Injury in Patients with High-Grade Gliomas. American Journal of Neuroradiology. 2019;40(2):253-259.  https://doi.org/10.3174/ajnr.a5952

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.